GRAIL to Install Josh Ofman as CEO on June 1, Founder Ragusa Retires
GRAIL CEO Bob Ragusa will retire June 1, 2026 after leading the spinout from Illumina, commercial growth and laboratory scaling; Josh Ofman will succeed him as CEO and join the board immediately. Ragusa will remain on the board until retirement date and serve as senior advisor through March 2027.
1. CEO Succession Plan
GRAIL announced that CEO Bob Ragusa will retire on June 1, 2026 after overseeing the spinout from Illumina, commercial expansion and the scaling of its North Carolina laboratory, with President Josh Ofman, MD, MSHS, stepping in as CEO and joining the board effective immediately.
2. Transition and Advisory Role
Ragusa will continue on GRAIL’s board until his retirement date and serve as a senior advisor through March 2027 to support a smooth leadership transition and maintain strategic continuity.
3. New CEO’s Credentials
Since joining GRAIL in 2019, Ofman has led policy, reimbursement and evidence programs for the Galleri multi-cancer early detection test, drawing on senior roles at Amgen, academic appointments and health policy organizations to drive regulatory engagement and scale operations.